H.C. Wainwright raised the firm’s price target on Tourmaline Bio (TRML) to $50 from $49 and keeps a Buy rating on the shares following the Q4 ...

Tourmaline Oil Corp. closed 7.6% below its 52-week high of C$70.83, which the company reached on February 21st.

Driving the consideration is the growing concern over power demand growth from data centers, which could double by 2029.

Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total ...

Tourmaline Oil Corp. closed 8.2% below its 52-week high of C$70.83, which the company achieved on February 21st.